Cargando…

A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer

Mycobacterium bovis Bacillus Calmette-Guérin (BCG) has the potential to promote adaptive immunity. We sought to examine the synergistic effect of BCG-CWS vaccination on cervical cancer patients undergoing standard treatments including surgery, chemotherapy, and/or radiation. We retrospectively analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Takeo, Takata, Emi, Sakamoto, Jinichi, Shioya, Akihiro, Yamada, Sohsuke, Takakura, Masahiro, Sasagawa, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803507/
https://www.ncbi.nlm.nih.gov/pubmed/36595982
http://dx.doi.org/10.1097/MD.0000000000032481
_version_ 1784861902184120320
author Shibata, Takeo
Takata, Emi
Sakamoto, Jinichi
Shioya, Akihiro
Yamada, Sohsuke
Takakura, Masahiro
Sasagawa, Toshiyuki
author_facet Shibata, Takeo
Takata, Emi
Sakamoto, Jinichi
Shioya, Akihiro
Yamada, Sohsuke
Takakura, Masahiro
Sasagawa, Toshiyuki
author_sort Shibata, Takeo
collection PubMed
description Mycobacterium bovis Bacillus Calmette-Guérin (BCG) has the potential to promote adaptive immunity. We sought to examine the synergistic effect of BCG-CWS vaccination on cervical cancer patients undergoing standard treatments including surgery, chemotherapy, and/or radiation. We retrospectively analyzed 103 patients (13 cases administered with BCG-CWS vaccine and 90 controls without BCG-CWS) who underwent a standard treatment for cervical cancer from 2005 to 2021. The BCG-CWS group underwent repeated intradermal injections of the BCG-CWS vaccine before or immediately after the standard therapy start from 2011 to 2018. The vaccination was repeated weekly for 1 month, and then every 4 weeks thereafter. The effectiveness of the BCG-CWS vaccination on cervical cancer treatment was evaluated by determining the hazard ratios of overall survival between the BCG-CWS group and the control group with multivariate analysis using the Cox model. Hazard ratios between 2 groups were determined after adjustment by clinical parameters including surgery, chemotherapy, radiation, age, clinical stage, presence of human papillomavirus, and pathology. Long-term follow-up revealed a significantly better prognosis (hazard ratio: 0.2108, P = .008 by the Cox model) for patients with cervical cancer in the BCG-CWS group compared to patients in the control group. Among patients with advanced cancer worse than stage IB2, some completely cleared the disease, whereas the others showed long-term survival with recurrence. BCG-CWS therapy appears to be an effective immune adjuvant therapy for cervical cancer, although randomized control studies are needed to confirm this. We also need to clarify the underlying mechanisms slowing the progression of cervical cancer in those receiving this vaccination. This study sheds light on the potential of immunostimulatory drugs such as BCG-CWS and suggests the important role of immunity for cancer elimination in combination therapy.
format Online
Article
Text
id pubmed-9803507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98035072023-01-03 A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer Shibata, Takeo Takata, Emi Sakamoto, Jinichi Shioya, Akihiro Yamada, Sohsuke Takakura, Masahiro Sasagawa, Toshiyuki Medicine (Baltimore) 5600 Mycobacterium bovis Bacillus Calmette-Guérin (BCG) has the potential to promote adaptive immunity. We sought to examine the synergistic effect of BCG-CWS vaccination on cervical cancer patients undergoing standard treatments including surgery, chemotherapy, and/or radiation. We retrospectively analyzed 103 patients (13 cases administered with BCG-CWS vaccine and 90 controls without BCG-CWS) who underwent a standard treatment for cervical cancer from 2005 to 2021. The BCG-CWS group underwent repeated intradermal injections of the BCG-CWS vaccine before or immediately after the standard therapy start from 2011 to 2018. The vaccination was repeated weekly for 1 month, and then every 4 weeks thereafter. The effectiveness of the BCG-CWS vaccination on cervical cancer treatment was evaluated by determining the hazard ratios of overall survival between the BCG-CWS group and the control group with multivariate analysis using the Cox model. Hazard ratios between 2 groups were determined after adjustment by clinical parameters including surgery, chemotherapy, radiation, age, clinical stage, presence of human papillomavirus, and pathology. Long-term follow-up revealed a significantly better prognosis (hazard ratio: 0.2108, P = .008 by the Cox model) for patients with cervical cancer in the BCG-CWS group compared to patients in the control group. Among patients with advanced cancer worse than stage IB2, some completely cleared the disease, whereas the others showed long-term survival with recurrence. BCG-CWS therapy appears to be an effective immune adjuvant therapy for cervical cancer, although randomized control studies are needed to confirm this. We also need to clarify the underlying mechanisms slowing the progression of cervical cancer in those receiving this vaccination. This study sheds light on the potential of immunostimulatory drugs such as BCG-CWS and suggests the important role of immunity for cancer elimination in combination therapy. Lippincott Williams & Wilkins 2022-12-30 /pmc/articles/PMC9803507/ /pubmed/36595982 http://dx.doi.org/10.1097/MD.0000000000032481 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5600
Shibata, Takeo
Takata, Emi
Sakamoto, Jinichi
Shioya, Akihiro
Yamada, Sohsuke
Takakura, Masahiro
Sasagawa, Toshiyuki
A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title_full A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title_fullStr A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title_full_unstemmed A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title_short A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
title_sort retrospective study of immunotherapy using the cell wall skeleton of mycobacterium bovis bacillus calmette-guérin (bcg-cws) for cervical cancer
topic 5600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803507/
https://www.ncbi.nlm.nih.gov/pubmed/36595982
http://dx.doi.org/10.1097/MD.0000000000032481
work_keys_str_mv AT shibatatakeo aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT takataemi aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT sakamotojinichi aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT shioyaakihiro aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT yamadasohsuke aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT takakuramasahiro aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT sasagawatoshiyuki aretrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT shibatatakeo retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT takataemi retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT sakamotojinichi retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT shioyaakihiro retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT yamadasohsuke retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT takakuramasahiro retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer
AT sasagawatoshiyuki retrospectivestudyofimmunotherapyusingthecellwallskeletonofmycobacteriumbovisbacilluscalmetteguerinbcgcwsforcervicalcancer